Reading ARVN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ARVN free→Reading ARVN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ARVN free→QuarterlyIQ Insights · ARVN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. As previously announced, on May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered into a license agreement (the “License Agreement”) with Rigel Pharmaceuticals, Inc. (“Rigel”), for the exclusive global development, manufacturing and commercializat…
Other Events. Following a strategic review of its pipeline, the Company has made the decision to re-prioritize its portfolio. As previously disclosed, in the second quarter of 2026, the Company announced that it had completed dose escalation enrollment of the Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring Kirsten rat sarcoma ("KRAS") G12D mutations. The Company is planning to complete this Phase 1 monotherapy dose escalation clinical trial and share clinical…
Results of Operations and Financial Condition. On May 12, 2026, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…
Entry into a Material Definitive Agreement. Rigel License Agreement On May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered into a license agreement (the “License Agreement”) with Rigel Pharmaceuticals, Inc. (“Rigel”). Pursuant to the License Agreement, the Co…
Other Events. On May 1, 2026, the Company issued a press release announcing that the FDA has granted approval for VEPPANU™ (vepdegestrant) for the treatment of adults with ER+/ HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine-based therapy. VEPPANU is the first-and-only FDA-approved PROteolysis Targeting Chimera (PROTAC) protein degrader, a type of heterobifunctional protein degra…
Results of Operations and Financial Condition. On February 24, 2026 , Arvinas, Inc. announced its financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Change in President, Chief Executive Officer and Chair of the Board of Directors On February 10, 2026, John Houston, Ph.D., notified Arvinas, Inc. (the “Company”) of his decision to resign as president, chief executive officer (“CEO”) and chairperson of the Company’s board of directors (the “Board”), effective February 12, 2026 (the “Effective Date…
Results of Operations and Financial Condition. On November 5, 2025, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…
Costs Associated with Exit or Disposal Activities. On September 17, 2025, management of Arvinas, Inc. (the “Company’), pursuant to authority delegated by the Board of Directors of the Company (the “Board”), committed to and approved a reduction in workforce of approximately 15% across roles in functional areas of the Company primarily related to vepdegestrant commercialization. The Company expects the workforce reduction will be substantially completed during the first quarter of 2026. The Co…
Regulation FD Disclosure. On September 17, 2025, the Company issued a press release providing an update on its collaboration with Pfizer, Inc. (“Pfizer”) and announcing further actions to support value creation. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…
Other Events. On September 17, 2025, the Company issued a press release providing an update on its collaboration with Pfizer and announcing further actions to support value creation, as discussed in additional detail below. Pfizer Collaboration Update The Company and Pfizer have jointly agreed to out-license the commercialization rights to vepdegestrant to a third party. Together, the companies have begun seeking a partner with the capabilities and expertise to maximize the commercial potenti…
Results of Operations and Financial Condition. On August 6, 2025, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. (b) On July 9, 2025, John Houston, Ph.D., Chairperson, President and Chief Executive Officer of Arvinas, Inc. (the “Company”) notified the Company of his plans to retire from his role as President and Chief Executive Officer of the Company following a search for, and the appointment of, a new Chief Executive Officer of the Company. Following his retirement as President and Chief Executive O…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. (b) On June 27, 2025, John Young notified Arvinas, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors (the “Board”) and the Compensation Committee of the Board, effective June 30, 2025. Mr. Young's decision to resign from the Board was not due to a disagreement on any matter related to the Company’s operations, policies or practices.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 4, 2025, Ian Taylor, Ph.D., President of Research and Development of Arvinas, Inc. (the “Company”), notified the Company of his decision to resign his employment with the Company and retire, effective June 6, 2025 (the “Resignation Date”). On the Resignation Date, in connection with his resignation, Dr. Taylor and the Company entered into a…
Costs Associated with Exit or Disposal Activities. On April 30, 2025, the Company's management, pursuant to authority delegated by the Board of Directors of the Company, committed the Company to and approved a reduction of the Company’s workforce by approximately 33% across all areas of the Company, as part of the Company's decision to streamline operations across the organization and enable the efficient progression of the Company’s portfolio. The Company expects the workforce reduction will…
Results of Operations and Financial Condition. On May 1, 2025, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2025 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am…
Results of Operations and Financial Condition. On February 11, 2025 , Arvinas, Inc. announced its financial results for the fourth quarter and year ended December 31, 2024 and provided a corporate update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARVINAS, INC. Date: January 22, 2025 By: /s/ Andrew Saik Andrew Saik Chief Financial Officer
Entry into a Material Definitive Agreement. On January 15, 2025, Arvinas Operations, Inc. (the “Company"), a wholly owned subsidiary of the Arvinas, Inc., entered into a Lease Termination Agreement with Science Park Development Corporation (the “Landlord”). Under the terms of the Lease Termination Agreement, the lease by and between the Company and the Landlord, dated November 15, 2019, as amended by First Amendment dated as of February 27, 2020, Second Amendment dated as of January 4, 2021 a…
Importance-ranked changes since the prior daily snapshot.
Confidence changed from 'medium' to 'high'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.